Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

Clinical trial NCT07694427 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07694427
Sponsor: GlaxoSmithKline
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Ovarian Neoplasms

Start date: 2026-10-09
Primary completion: 2029-09-06
Enrollment: 720

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.